help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, A. S.
Right arrow Articles by Elahi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, A. S.
Right arrow Articles by Elahi, D.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 7 2399-2404
Copyright © 1998 by The Endocrine Society

Original Studies

Insulinotropic Hormone Glucagon-Like Peptide-1-(7–37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia1

Alice S. Ryan, Josephine M. Egan, Joel F. Habener2 and Dariush Elahi

Laboratory of Clinical Physiology, Gerontology Research Center, National Institute on Aging, National Institutes of Health (J.M.E., D.E.); and the Division of Gerontology, Department of Medicine, University of Maryland School of Medicine (A.S.R., D.E.), Baltimore, Maryland 21201; and the Department of Medicine, Massachusetts General Hospital (J.F.H., D.E.), and the Laboratory of Molecular Endocrinology, Howard Hughes Medical Institute (J.F.H.), Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Dariush Elahi, Ph.D., Geriatrics Research Laboratory GRJ-1215, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114.

Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments insulin secretion in response to meals and lowers blood glucose levels in both type 1 and type 2 diabetic subjects. It has been proposed that a substantial component of the glucose-lowering effects of GLP-1 occurs via insulin-independent mechanisms. However, the interpretations of the studies have been controversial. This study was conducted to examine whether glucagon-like peptide (GLP-1) has an insulin-like effect during euglycemia. Nine young lean men (age, 25 ± 1.4 yr; body mass index, 24.0 ± 0.7 kg/m2) volunteered to participate in two euglycemic clamp studies (n = 18 clamps) for 120 min. The initial clamp was performed with a primed continuous infusion of GLP-1 at a final rate of 1.5 pmol/kg·min from 0–60 min. At 60 min, the GLP-1 infusion was terminated, and euglycemia was maintained from 60–120 min. After the GLP-1 study, each individual’s plasma insulin level was measured. A second study was performed that was identical to the first, with the infusion of regular insulin in place of GLP-1. Insulin infusion rates were designed in each individual to simulate plasma insulin levels produced during the GLP-1 infusion. The rate of disappearance of glucose was calculated for each subject. Basal plasma insulin levels were similar between studies and averaged 49 ± 5 pmol/L. Basal GLP-1 levels were also similar (6.0 ± 1.0 pmol/L). In response to the GLP-1 infusion, although basal plasma glucose levels were clamped, significant increases in insulin occurred in all subjects (P < 0.001). With the nearly identical plasma insulin levels during the two studies (30–60 min levels: GLP-1 study, 151 ± 48; insulin study, 146 ± 31 pmol/L), the rate of disappearance of glucose progressively increased in response to both GLP-1 and insulin infusions, but was not significantly different between the studies. The design of the study necessitated conducting the GLP-1 study first, which may have been accompanied by a greater stress than the second study. We, therefore, measured cortisol levels. Basal cortisol (and ACTH) levels were not different. However, cortisol levels significantly increased during the GLP-1 infusions, and this was preceded by an increase in ACTH levels. Somatostatin levels were not different either basally or during the clamps. We conclude that in the euglycemic state, an acute infusion of GLP-1 does not have insulin-like effects in lean nondiabetic men. Intravenous administration of GLP-1 activates hypothalamic neuroendocrine neurons.




This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
B. E. Dunning and J. E. Gerich
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Endocr. Rev., May 1, 2007; 28(3): 253 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Dardevet, M. C. Moore, C. A. DiCostanzo, B. Farmer, D. W. Neal, W. Snead, M. Lautz, and A. D. Cherrington
Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors
Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G806 - G814.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. A. Nikolaidis, A. Doverspike, T. Hentosz, L. Zourelias, Y.-T. Shen, D. Elahi, and R. P. Shannon
Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Dardevet, M. C. Moore, D. Neal, C. A. DiCostanzo, W. Snead, and A. D. Cherrington
Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E75 - E81.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, N. Greig, H. Tildesley, J. F. Habener, J. M. Egan, and D. Elahi
Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes
Diabetes Care, October 1, 2003; 26(10): 2835 - 2841.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. J. Drucker
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Diabetes Care, October 1, 2003; 26(10): 2929 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. S. Fineman, T. A. Bicsak, L. Z. Shen, K. Taylor, E. Gaines, A. Varns, D. Kim, and A. D. Baron
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
Diabetes Care, August 1, 2003; 26(8): 2370 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. M. Egan, G. S. Meneilly, and D. Elahi
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1072 - E1079.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, M. R.W. Ehlers, J. M. Egan, and D. Elahi
Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes
Diabetes Care, March 1, 2003; 26(3): 837 - 842.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Perry, N. J. Haughey, M. P. Mattson, J. M. Egan, and N. H. Greig
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 881 - 888.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Egan, G. S. Meneilly, J. F. Habener, and D. Elahi
Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3768 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Egan, A. R. Clocquet, and D. Elahi
The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1282 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Perry, D. K. Lahiri, D. Chen, J. Zhou, K. T. Y. Shaw, J. M. Egan, and N. H. Greig
A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 958 - 966.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, and D. Elahi
Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M681 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, D. T. Finegood, and D. Elahi
Effect of Glucagon-Like Peptide 1 on Non-Insulin-Mediated Glucose Uptake in the Elderly Patient With Diabetes
Diabetes Care, November 1, 2001; 24(11): 1951 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, and D. Elahi
Glucagon-Like Peptide-1 (7-37) Augments Insulin Release in Elderly Patients With Diabetes
Diabetes Care, May 1, 2001; 24(5): 964 - 965.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Bertin, P. Arner, J. Bolinder, and E. Hagström-Toft
Action of Glucagon and Glucagon-Like Peptide-1-(7-36) Amide on Lipolysis in Human Subcutaneous Adipose Tissue and Skeletal Muscle in Vivo
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1229 - 1234.
[Abstract] [Full Text]

Home page
 DiabetesHome page
A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, F. W. Schwenk, J. J. Holst, and R. A. Rizza
Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes
Diabetes, March 1, 2001; 50(3): 565 - 572.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
N. J. MacLusky, S. Cook, L. Scrocchi, J. Shin, J. Kim, F. Vaccarino, S. L. Asa, and D. J. Drucker
Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling
Endocrinology, February 1, 2000; 141(2): 752 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. J. Kieffer and J. Francis Habener
The Glucagon-Like Peptides
Endocr. Rev., December 1, 1999; 20(6): 876 - 913.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society